Marcela K. Preininger

MFN may never become law, but its signal still matters The industry is still parsing the implications of the new MFN framework established by May's Executive Order. While practical policy details remain undefined, the signal is unmistakable: the administration wants to bring pharma to the table on drug pricing. The real question is how the industry responds. Does it see MFN as a threat that it must navigate or as an opportunity to lead?

The swell that may not break Where biosimilars stand now A record-breaking patent cliff is on the horizon, but headwinds may shrink the anticipated "wave" to a ripple. While past launches were a smash hit, recent ones are a wake-up call. Why the water's so choppy What's holding biosimilars back? There are three main culprits holding things back: policy uncertainty from the Inflation Reduction Act (IRA), tricky reimbursement economics, and PBMs acting as gatekeepers.

Next-Generation Antibodies: A New Era In Immuno-Oncology As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes...